CAS: 73406-97-0; 1-(5-Bromopyridin-2-yl)Piperazine

该化合物是一种化学化合物,其特点是以青铜原子和酸来取代环,该化合物通常展示一种分子结构,其中包括六人芳香环(pyrodine)和子环,这是一个饱和的六人环,内含两个氮原子.溴原子的存在会引入卤素特性,有可能影响化合物的再活性和生物活动.5-Bromo-2-(iprorazin-1-yl),经常因其药理特性而进行研究,因为人们知道,这种分子衍生物会展示各种生物活动,包括抗微生物和抗扰动效应.该化合物的溶性,稳定性和与生物目标的相互作用可能因其结构特征而不同.此外,该化合物可能作为医药化学中较复杂的分子合成的中间体.应当参考安全数据,以便处理和使用,如任何化学物质一样.

结构式图片

欧盟法规

C&L通报

上下游产品

2,5-dibromopyridine diethyl ether 1-t-Butoxycarbonylpiperazine piperazine 1-[5-(benzyloxy)pyridin-2-yl]piperazine 1-[4-(5-bromopyridin-2-yl)piperazin-1-yl]ethanone 2,6-dichloro-4-(6-(piperazin-1-yl)pyridin-3-yl)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide

合成工艺路线路线简述

    📜2-氟-5-溴吡啶置于盐酸,Potassium Carbonate体系中,用 1,4-二氧六环,二氯甲烷,N,N-二甲基甲酰胺 作为反应溶剂,化学反应 17.0H,反应生成 1-(5-溴吡啶)-2-哌嗪
    参考文献:吡唑并[1,5-A]吡啶类化合物及其制备方法和应用
    标题:吡唑并[1,5-A]吡啶类化合物及其制备方法和应用
    摘要:本发明涉及一种吡唑并[1,5‑a]吡啶类化合物及其制备方法和应用,包括所述化合物作为活性成分的药物组合物或其药学上可接受的盐.本发明进一步涉及式(I)化合物在用于治疗和预防可用野生型,基因融合型及突变型(包括但不限于g804和g810)Ret激酶抑制剂治疗的疾病,包括由ret激酶介导的疾病或病症.

    海关参考信息

    专利信息


    专利号:RU-2128659-C1
    优先权日:1993-02-19
    标题:Substituted derivatives of azolone, method of their synthesis, pharmaceutical composition and method of its preparing

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    合成参考文献


    参考文献:10.1126/science.abo7201
    摘要:Boby ML, Fearon D, Ferla M, Filep M, Koekemoer L, Robinson MC; COVID Moonshot Consortium‡, Chodera JD, Lee AA, London N, von Delft A, von Delft F, Achdout H, Aimon A, Alonzi DS, Arbon R, Aschenbrenner JC, Balcomb BH, Bar-David E, Barr H, Ben-Shmuel A, Bennett J, Bilenko VA, Borden B, Boulet P, Bowman GR, Brewitz L, Brun J, Bvnbs S, Calmiano M, Carbery A, Carney DW, Cattermole E, Chang E, Chernyshenko E, Clyde A, Coffland JE, Cohen G, Cole JC, Contini A, Cox L, Croll TI, Cvitkovic M, De Jonghe S, Dias A, Donckers K, Dotson DL, Douangamath A, Duberstein S, Dudgeon T, Dunnett LE, Eastman P, Erez N, Eyermann CJ, Fairhead M, Fate G, Fedorov O, Fernandes RS, Ferrins L, Foster R, Foster H, Fraisse L, Gabizon R, García-Sastre A, Gawriljuk VO, Gehrtz P, Gileadi C, Giroud C, Glass WG, Glen RC, Glinert I, Godoy AS, Gorichko M, Gorrie-Stone T, Griffen EJ, Haneef A, Hassell Hart S, Heer J, Henry M, Hill M, Horrell S, Huang QYJ, Huliak VD, Hurley MFD, Israely T, Jajack A, Jansen J, Jnoff E, Jochmans D, John T, Kaminow B, Kang L, Kantsadi AL, Kenny PW, Kiappes JL, Kinakh SO, Kovar B, Krojer T, La VNT, Laghnimi-Hahn S, Lefker BA, Levy H, Lithgo RM, Logvinenko IG, Lukacik P, Macdonald HB, MacLean EM, Makower LL, Malla TR, Marples PG, Matviiuk T, McCorkindale W, McGovern BL, Melamed S, Melnykov KP, Michurin O, Miesen P, Mikolajek H, Milne BF, Minh D, Morris A, Morris GM, Morwitzer MJ, Moustakas D, Mowbray CE, Nakamura AM, Neto JB, Neyts J, Nguyen L, Noske GD, Oleinikovas V, Oliva G, Overheul GJ, Owen CD, Pai R, Pan J, Paran N, Payne AM, Perry B, Pingle M, Pinjari J, Politi B, Powell A, Pšenák V, Pulido I, Puni R, Rangel VL, Reddi RN, Rees P, Reid SP, Reid L, Resnick E, Ripka EG, Robinson RP, Rodriguez-Guerra J, Rosales R, Rufa DA, Saar K, Saikatendu KS, Salah E, Schaller D, Scheen J, Schiffer CA, Schofield CJ, Shafeev M, Shaikh A, Shaqra AM, Shi J, Shurrush K, Singh S, Sittner A, Sjö P, Skyner R, Smalley A, Smeets B, Smilova MD, Solmesky LJ, Spencer J, Strain-Damerell C, Swamy V, Tamir H, Taylor JC, Tennant RE, Thompson W, Thompson A, Tomásio S, Tomlinson CWE, Tsurupa IS, Tumber A, Vakonakis I, van Rij RP, Vangeel L, Varghese FS, Vaschetto M, Vitner EB, Voelz V, Volkamer A, Walsh MA, Ward W, Weatherall C, Weiss S, White KM, Wild CF, Witt KD, Wittmann M, Wright N, Yahalom-Ronen Y, Yilmaz NK, Zaidmann D, Zhang I, Zidane H, Zitzmann N, Zvornicanin SN. Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors. Science. 2023 Nov 10;382(6671):eabo7201.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知